Patents by Inventor Leigh MacConell

Leigh MacConell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING A FXR AGONIST AND A FIBRATE FOR USE IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE
    Publication number: 20220226350
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventors: Leigh A. MACCONELL, Richard PENCEK
  • METHODS OF USING OBETICHOLIC ACID
    Publication number: 20220184099
    Abstract: The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis.
    Type: Application
    Filed: July 23, 2021
    Publication date: June 16, 2022
    Inventors: Jeffrey EDWARDS, Sharon KARAN, Jason CAMPAGNA, Leigh A. MACCONELL
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20220133745
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: December 6, 2021
    Publication date: May 5, 2022
    Inventors: Richard Gail LANCASTER, Kay K. OLMSTEAD, Masashi KAGIHIRO, Mitsuhiro MATONO, Ikuko TAOKA, Mark PRUZANSKI, David SHAPIRO, Roya HOOSHMAND-RAD, Richard PENCEK, Cathi SCIACCA, Lise ELIOT, Jeffrey EDWARDS, Leigh MACCONELL, Tonya MARMON
  • Compositions of obeticholic acid and methods of use
    Patent number: 10758549
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: September 1, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Compositions of obeticholic acid and methods of use
    Patent number: 10751349
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: August 25, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT
    Publication number: 20200222509
    Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 16, 2020
    Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mark Fineman, Leigh Macconell, Kristin Taylor
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20200171053
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 4, 2020
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • METHODS OF USING OBETICHOLIC ACID
    Publication number: 20200147108
    Abstract: The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis.
    Type: Application
    Filed: November 6, 2019
    Publication date: May 14, 2020
    Inventors: Jeffrey Edwards, Sharon Karan, Jason Campagna, Leigh MacConell
  • Compositions of obeticholic acid and methods of use
    Patent number: 10646499
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20200054650
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 20, 2020
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20200046736
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 13, 2020
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20200046735
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 13, 2020
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20190255071
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: January 15, 2019
    Publication date: August 22, 2019
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20190076446
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: July 9, 2018
    Publication date: March 14, 2019
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT
    Publication number: 20180333468
    Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Type: Application
    Filed: February 5, 2018
    Publication date: November 22, 2018
    Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mark FINEMAN, Leigh MACCONELL, Kristin TAYLOR
  • Compositions of obeticholic acid and methods of use
    Patent number: 10052337
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 21, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Methods for treating diabetes and reducing body weight
    Patent number: 9884092
    Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 6, 2018
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mark Fineman, Leigh MacConell, Kristin Taylor
  • COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
    Publication number: 20170035784
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Application
    Filed: April 26, 2016
    Publication date: February 9, 2017
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT
    Publication number: 20160271225
    Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Type: Application
    Filed: May 31, 2016
    Publication date: September 22, 2016
    Inventors: Mark FINEMAN, Leigh MACCONELL, Kristin TAYLOR
  • EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES
    Publication number: 20150238568
    Abstract: Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mark Fineman, Leigh MacConell, Kristin Taylor